Zurcher Kantonalbank (Zurich Cantonalbank) Acumen Pharmaceuticals, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2023 Jan 30, 2024	SELL	$1.86 - $4.48 $5,542 - $13,350	-2,980 Reduced 87.83%	413 $1,000
Q3 2023 Oct 25, 2023	BUY	$4.15 - $9.72 $14,080 - $32,979	3,393 New	3,393 $14,000

Others Institutions Holding ABOS

# of Institutions

Shares Held

41.8M

Call Options Held

57.7K

Put Options Held

749K

Ra Capital Management, L.P. Boston, MA

14.9M
Shares

$25.4 Million
0.52% of portfolio
Franklin Resources Inc San Mateo, CA

3.55M
Shares

$6.03 Million
0.0% of portfolio
Sands Capital Ventures, LLC Arlington, VA

3.42M
Shares

$5.81 Million
4.37% of portfolio
Rock Springs Capital Management LP Baltimore, MD

2.3M
Shares

$3.91 Million
0.19% of portfolio
Black Rock Inc. New York, NY

2.16M
Shares

$3.67 Million
0.0% of portfolio

View Full List

About Acumen Pharmaceuticals, Inc.

Ticker ABOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,503,100
Market Cap $68.9M
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...

More about ABOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account